|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM230189008 |
| 003 |
DE-627 |
| 005 |
20240508231942.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.07.002
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1401.xml
|
| 035 |
|
|
|a (DE-627)NLM230189008
|
| 035 |
|
|
|a (NLM)23962407
|
| 035 |
|
|
|a (PII)S1521-6616(13)00190-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhao, Wenpu
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.11.2013
|
| 500 |
|
|
|a Date Revised 08.05.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2013.
|
| 520 |
|
|
|a PPAR-γ agonists can suppress autoimmune responses and renal inflammation in murine lupus but the mechanisms implicated in this process remain unclear. We tested the effect of the PPAR-γ agonist pioglitazone in human lupus and control PBMCs with regard to gene regulation and various functional assays. By Affymetrix microarray analysis, several T cell-related pathways were significantly highlighted in pathway analysis in lupus PBMCs. Transcriptional network analysis showed IFN-γ as an important regulatory node, with pioglitazone treatment inducing transcriptional repression of various genes implicated in T cell responses. Confirmation of these suppressive effects was observed specifically in purified CD4+ T cells. Pioglitazone downregulated lupus CD4+ T cell effector proliferation and activation, while it significantly increased proliferation and function of lupus T regulatory cells. We conclude that PPAR-γ agonists selectively modulate CD4+ T cell function in SLE supporting the concept that pioglitazone and related,-agents should be explored as potential therapies in this disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Gene expression
|
| 650 |
|
4 |
|a Systemic lupus erythematosus;
|
| 650 |
|
4 |
|a T cells;
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a PPAR gamma
|2 NLM
|
| 650 |
|
7 |
|a Thiazolidinediones
|2 NLM
|
| 650 |
|
7 |
|a DNA
|2 NLM
|
| 650 |
|
7 |
|a 9007-49-2
|2 NLM
|
| 650 |
|
7 |
|a Pioglitazone
|2 NLM
|
| 650 |
|
7 |
|a X4OV71U42S
|2 NLM
|
| 700 |
1 |
|
|a Berthier, Celine C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lewis, Emily E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a McCune, W Joseph
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kretzler, Matthias
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kaplan, Mariana J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 1 vom: 06. Okt., Seite 119-32
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:1
|g day:06
|g month:10
|g pages:119-32
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.07.002
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 149
|j 2013
|e 1
|b 06
|c 10
|h 119-32
|